In 2010, New guidelines report was issued by the CDC for the treatment of sexually transmitted diseases (STDs).

The guidelines recommend

• Quinolones no longer be used for the treatment of gonorrhea and associated conditions such as pelvic inflammatory disease.
• Following are the patient-applied treatments for external genital warts: podofilox 0.5% solution or gel or imiquimod 5% cream.
• Regimens for treating pregnant women with Chlamydia trachomatis are azithromycin 1 g orally in a single dose or amoxicillin 500 mg orally three times a day for 7 days.

• The guidelines note that quinolone-resistant Neisseria gonorrhoeae is now widely disseminated in the United States and the world.
• Emphasizes that cephalosporins are the only class of antimicrobials recommended and available for treatment of gonorrhea in the United States.
• Recommends ceftriaxone 250 mg IM in a single dose for the treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum.
• If this is not an option, CDC recommends cefixime 400 mg orally in a single dose or single-dose injectible cephalosporin regimens plus azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice a day for 7 days.
• The recommendation for uncomplicated gonococcal infections of the pharynx is ceftriaxone 250 mg IM in a single dose plus azithromycin 1 g in a single dose or doxycycline 100 mg orally twice a day for 7 days.
• The CDC recommends the following treatment for women showing symptoms of bacterial vaginosis: metronidazole 500 mg orally twice a day for 7 days or metronidazole gel 0.75%, one full applicator (5 g) intravaginally, once a day for 5 days, or clindamycin cream 2%, one full applicator (5 g) intravaginally at bedtime for 7 days.
• Alternative regimens for bacterial vaginosis recommended by the CDC include: tinidazole (either 2 g orally once daily for 2 days or 1 g orally daily for 5 days) or clindamycin (300 mg orally twice daily for 7 days, or clindamycin ovules 100 mg intravaginally once at bedtime for 3 days).

Since there is no clinical evidence that which treatment is superior to another for external genital warts. Therefore, treatment should be guided by patient preference.

The CDC report also provides extensive discussion on the role of Mycoplasma genitalium and trichomoniasis in urethritis/cervicitis and treatment-related implications.
The full report appears in MMWR Morbidity and Mortality Report, Dec. 17, 2010, http://www.cdc.gov/std/treatment/2010/STD-Treatment-2010-RR5912.pdf).

Reference: http://drugtopics.modernmedicine.com/drugtopics/Modern+Medicine+Now/CDC-report-updates-STD-treatments/ArticleStandard/Article/detail/711831?contextCategoryId=40152